Grifols S.A
Research Grifols S.A (OZTA) on Bullrun: valuation model: 19.9% undervalued, market cap EUR 6.05B, P/E 14.6, dividend yield 0.9%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOZTA
- ExchangeF
- CountrySpain
- SectorHealthcare
- IndustryDrug Manufacturers - General
- CurrencyEUR
- Valuation signal19.9% undervalued
- Market capEUR 6.05B
- P/E14.6
- Dividend yield0.9%
- Financial periodFY2024
- RevenueEUR 7.21B
- Revenue growth9.4%
- Net incomeEUR 212.81M
- Free cash flowEUR 669.63M
- Gross margin38.7%
Valuation Snapshot
Bullrun's latest valuation model marks Grifols S.A as 19.9% undervalued; latest market cap is EUR 6.05B; P/E is 14.6; dividend yield is 0.9%.
About Grifols S.A
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas;
Frequently asked questions
Is Grifols S.A overvalued or undervalued?
Bullrun's valuation model currently marks Grifols S.A as 19.9% undervalued.
What is Grifols S.A's market cap?
Grifols S.A's market capitalization is EUR 6.05B.
What is Grifols S.A's P/E ratio?
Grifols S.A's price-to-earnings (P/E) ratio is 14.6.
Does Grifols S.A pay a dividend?
Grifols S.A has a dividend yield of 0.9%.
What does Grifols S.A do?
Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.